Home > Healthcare > Medical Devices > Medical Supplies > Breast Cancer Core Needle Biopsy (CNB) Market

Breast Cancer Core Needle Biopsy (CNB) Market Share

Report ID: GMI11100
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Breast Cancer Core Needle Biopsy Market Share

The breast cancer core needle biopsy (CNB) market is characterized by innovation and advanced imaging solutions. Key competitors focus on enhancing precision, minimizing patient discomfort, and improving biopsy outcomes through cutting-edge technology. Companies invest in developing minimally invasive devices with real-time imaging capabilities, such as ultrasound and MRI-guided systems.

Breast Cancer Core Needle Biopsy Market Companies

Few of the prominent players operating in the breast cancer core needle biopsy (CNB) treatment industry include:

Aurora Imaging Technology Inc.
BD
Devicor Medical Products, Inc.
Fujifilm Holdings
Hologic, Inc.
Insight Medbotics
McLaren
Rye Radiology
Siemens Healthcare Private Limited
Sentinelle Medical Inc.
Tampa General

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Breast cancer core needle biopsy industry size was valued USD 776.5 million in 2023 and will grow at a 7.8% CAGR between 2024 and 2032, fueled by rising breast cancer incidence and increased awareness of early detection.

Breast cancer CNB industry from the ultrasound-guided segment will achieve 7.6% CAGR through 2032, driven by its precision and real-time imaging capabilities.

U.S. breast cancer core needle biopsy industry size was USD 320.3 million in 2023, attributed to its advanced healthcare infrastructure and high incidence of breast cancer.

Aurora Imaging Technology Inc., BD, Devicor Medical Products, Inc., Fujifilm Holdings, Hologic, Inc., Insight Medbotics, McLaren, Rye Radiology, Siemens Healthcare Private Limited, and Sentinelle Medical Inc, among others.